Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells
- PMID: 22872166
- DOI: 10.1097/IGC.0b013e318262aa53
Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells
Abstract
Objective: Analysis of tumor-infiltrating lymphocytes (TILs) is one of the cornerstones for the understanding of immune responses prevailing in the tumor microenvironment. We studied TILs from squamous cell carcinoma of the cervix ex vivo without proliferating them in vitro before analysis.
Methods: Whereas TILs were magnetic activated cell separation enriched and flow sorted into CD4 CD25 (regulatory T cells [Tregs]), CD4 CD25 (effector T cells [Teffs]) were directly purified by flow cytometry, and both these subsets were characterized phenotypically and functionally. Tissue sections were probed for interleukin 4 (IL-4) and interferon γ.
Results: Effector T cells constitutively expressed both interferon γ and IL-4 prototypical cytokines of TH1 and TH2, respectively, and were able to proliferate and secrete higher quantities of both cytokines in response to anti-CD3/anti-CD28 and autologous tumor lysates. Only 53% of cervical cancer Tregs were FOXP3, elaborated transforming growth factor β1, and IL-10 and were able to inhibit both T helper subsets.
Conclusions: Intratumoral Teffs represented functionally active subsets of both TH1 and TH2 that were not anergic but were suppressed by multiple Treg subsets, which comprised FOXP3 + Tregs and Tregs secreting transforming growth factor β1 and IL-10. These results imply that the microenvironment of cervical carcinomas harbored both TH1 and TH2 subsets of CD4 Teffs that were functionally active but were perhaps unable to perform because of the overpowering effect of Tregs.
Similar articles
-
Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.Gynecol Oncol. 2001 Jun;81(3):424-32. doi: 10.1006/gyno.2001.6200. Gynecol Oncol. 2001. PMID: 11371133
-
CD4+CD25+ T cells alloactivated ex vivo by IL-2 or IL-4 become potent alloantigen-specific inhibitors of rejection with different phenotypes, suggesting separate pathways of activation by Th1 and Th2 responses.Blood. 2009 Jan 8;113(2):479-87. doi: 10.1182/blood-2008-05-156612. Epub 2008 Sep 30. Blood. 2009. PMID: 18827184
-
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54. doi: 10.1158/1078-0432.CCR-07-0472. Clin Cancer Res. 2007. PMID: 17671115
-
Alloantigen specific T regulatory cells in transplant tolerance.Int Immunopharmacol. 2009 May;9(5):570-4. doi: 10.1016/j.intimp.2009.01.016. Epub 2009 Jan 29. Int Immunopharmacol. 2009. PMID: 19539571 Review.
-
Stability of Regulatory T Cells Undermined or Endorsed by Different Type-1 Cytokines.Adv Exp Med Biol. 2015;850:17-30. doi: 10.1007/978-3-319-15774-0_2. Adv Exp Med Biol. 2015. PMID: 26324343 Review.
Cited by
-
Identifying Molecular Changes in Early Cervical Cancer Samples of Patients That Developed Metastasis.Front Oncol. 2022 Jan 11;11:715077. doi: 10.3389/fonc.2021.715077. eCollection 2021. Front Oncol. 2022. PMID: 35087740 Free PMC article.
-
Expression of CTLA-4 and Foxp3 in peripheral blood T cells of patients with squamous cell laryngeal carcinoma.Contemp Oncol (Pozn). 2013;17(4):370-7. doi: 10.5114/wo.2013.37219. Epub 2013 Oct 7. Contemp Oncol (Pozn). 2013. PMID: 24592125 Free PMC article.
-
Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives.Mol Ther Oncolytics. 2021 Jul 21;22:410-430. doi: 10.1016/j.omto.2021.07.006. eCollection 2021 Sep 24. Mol Ther Oncolytics. 2021. PMID: 34553029 Free PMC article. Review.
-
Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer.Cancer Immunol Immunother. 2021 Jun;70(6):1649-1665. doi: 10.1007/s00262-020-02807-1. Epub 2020 Dec 10. Cancer Immunol Immunother. 2021. PMID: 33301062 Free PMC article.
-
Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion.Oncoimmunology. 2015 Mar 19;4(6):e1008334. doi: 10.1080/2162402X.2015.1008334. eCollection 2015 Jun. Oncoimmunology. 2015. PMID: 26155412 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials